🏛️ Verified NIH Record • Updated 2026-08-04
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described (NCT04122976)
Darolutamide Observational Study in Non-metastatic Castration-resistant Prostate Cancer Patients
🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Bayer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to find out in the real-world setting, if darolutamide is safe and effective for patients diagnosed with prostate cancer that has not spread to other parts of the body. When a patient is enrolled to the study, his/her physician would have already made the decision to treat patient with darolutamide per local standard practice.
Who can join: Review the eligibility criteria below.
Location: Urology Centers of Alabama — Homewood, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (40 Sites)
Showing the first 25 of 40 sites.
- Urology Centers of Alabama — Homewood, Alabama
- Arizona Institute of Urology — Tucson, Arizona
- Genesis Comprehensive Prostate Cancer Center — San Diego, California
- The Urology Center of Colorado — Denver, Colorado
- New Jersey Urology — Englewood, Colorado
- Manatee Medical Research Institute — Bradenton, Florida
- Advanced Urology Institute — Daytona Beach, Florida
- Research by Design, LLC — Chicago, Illinois
- First Urology, PSC — Jeffersonville, Indiana
- Wichita Urology Group — Wichita, Kansas
- Southcoast Centers for Cancer Care — Fairhaven, Massachusetts
- Oregon Urology Institute — Springfield, Massachusetts
- Beacon Cancer Care — Beacon, New York
- Integrated Medical Professionals, PLLC — North New Hyde Park, New York
- Premier Medical Group of the Hudson Valley, PC — Poughkeepsie, New York
- Associated Medical Professional Urology — Syracuse, New York
- Associated Urologists of NC — Raleigh, North Carolina
- Keystone Urology Specialists — Lancaster, Pennsylvania
- Vanderbilt University Medical Center — Nashville, Tennessee
- Urology San Antonio — San Antonio, Texas
- Baylor Scott & White Medical Center - Temple — Temple, Texas
- Urology of Virginia — Virginia Beach, Virginia
- University of Washington — Seattle, Washington
- MultiCare Institute for Research & Innovation — Tacoma, Washington
- Many locations — Multiple Locations,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC — Homewood, Alabama
- Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
- A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
- Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland
Explore by condition: All Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.